Charles River Laboratories (NYSE: CRL) has completed its acquisition of HemaCare Corporation (OTCMKTS: HEMA) for $380 million in cash, or $25.40 per HemaCare share. [Read more…]
Adding Cell Types Supports Drug Discovery of Disease-Modifying Therapies for Neurodegenerative Diseases and Triggues U.S. $6 M Payment to Evotec
Hamburg, Germany, January 7, 2020 – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company (NYSE:BMY) following the decision to expand the collaboration to include additional cell lines.
Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients’ symptoms and there is a huge unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases.
This collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s unique technology platforms in conjunction with the human iPSC based platform, which is one of the largest and most sophisticated platforms in the industry. The iPSC partnership between Bristol-Myers Squibb and Evotec has already been expanded with additional cell lines several times. [Read more…]
SAN ANTONIO, TX and ANN ARBOR, MI, January 8, 2020 – StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) are pleased to announce that StemBioSys has acquired a majority stake in Cartox. StemBioSys will acquire all remaining equity of Cartox subject to the achievement of certain milestones. [Read more…]
An RMAT is a “Regenerative Medicine Advanced Therapy” designation and this is a list of the 39 publicly announced RMAT Designations to date. At least 5 more have bee approved, as the FDA states it has received 115 requests and issued 44. This means 38% of RMAT requests get approved.
Sponsors of cell and gene therapies are eligible to obtain an RMAT designation from the U.S. FDA if their product is intended to treat serious or life-threatening diseases and there is preliminary clinical evidence that it can address unmet medical needs.
Recent additions include Adaptimmune Therapeutics T-cell therapy ADP-A2M4 for the treatment of Synovial Sarcoma n December 3, 2019, as well as Bristol-Myers Squibb’s Liso-cel, an autologous anti-CD19 CAR-T cell therapy.
On December 3, 2019, Adaptimmune Therapeutics (Nasdaq:ADAP) announced it has been granted an Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. FDA for ADP-A2M4 in the treatment of Synovial Sarcoma. Previously, the FDA had awarded an Orphan Drug Designation (ODD) to ADP-A2M4 for the treatment of soft tissue sarcomas.